In the first phase 1 dose-escalation study, 40 patients with relapsed or refractory CD33-positive acute myeloid leukemia (AML) were treated with 0.25 mg/m2 to 9 mg/m2 of gemtuzumab ozogamicin [79]. This evidence concerns the gene CD33 and acute myeloid leukemia.